Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment.

Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR Jr, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen PS, Petersen RC, Weiner MW; Alzheimer's Disease Neuroimaging Initiative..

Alzheimers Dement. 2011 Sep;7(5):514-20. doi: 10.1016/j.jalz.2010.12.010.

2.

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.

Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR Jr, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative..

Neuroimage Clin. 2014 Jan 4;4:461-72. doi: 10.1016/j.nicl.2013.12.012. eCollection 2014.

3.

Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype.

Bangen KJ, Clark AL, Werhane M, Edmonds EC, Nation DA, Evangelista N, Libon DJ, Bondi MW, Delano-Wood L; Alzheimer’s Disease Neuroimaging Initiative..

J Alzheimers Dis. 2016 Mar 29;52(3):849-61. doi: 10.3233/JAD-150900.

4.

MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.

Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative..

Brain. 2009 Apr;132(Pt 4):1067-77. doi: 10.1093/brain/awp007. Epub 2009 Feb 27.

5.

A Multi-Cohort Study of ApoE ɛ4 and Amyloid-β Effects on the Hippocampus in Alzheimer's Disease.

Khan W, Giampietro V, Banaschewski T, Barker GJ, Bokde AL, Büchel C, Conrod P, Flor H, Frouin V, Garavan H, Gowland P, Heinz A, Ittermann B, Lemaître H, Nees F, Paus T, Pausova Z, Rietschel M, Smolka MN, Ströhle A, Gallinat J, Vellas B, Soininen H, Kloszewska I, Tsolaki M, Mecocci P, Spenger C, Villemagne VL, Masters CL, Muehlboeck JS, Bäckman L, Fratiglioni L, Kalpouzos G, Wahlund LO, Schumann G, Lovestone S, Williams SC, Westman E, Simmons A; Alzheimer–s Disease Neuroimaging Initiative.; AddNeuroMed Consortium, Australian, Imaging, Biomarkers, and Lifestyle Study Research Group.; IMAGEN consortium..

J Alzheimers Dis. 2017;56(3):1159-1174. doi: 10.3233/JAD-161097.

6.

Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.

Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative..

Ann Neurol. 2010 Mar;67(3):308-16. doi: 10.1002/ana.21953.

7.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative..

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
8.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
9.

APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease.

Lim YY, Villemagne VL, Pietrzak RH, Ames D, Ellis KA, Harrington K, Snyder PJ, Martins RN, Masters CL, Rowe CC, Maruff P; Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group..

Neurobiol Aging. 2015 Mar;36(3):1239-44. doi: 10.1016/j.neurobiolaging.2014.12.008. Epub 2014 Dec 11.

PMID:
25559335
10.

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.

Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, Shaw LM, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative..

Ann Neurol. 2013 Dec;74(6):826-36. doi: 10.1002/ana.23908.

11.

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis.

Mattsson N, Insel PS, Palmqvist S, Stomrud E, van Westen D, Minthon L, Zetterberg H, Blennow K, Hansson O.

Nat Commun. 2016 Mar 7;7:10918. doi: 10.1038/ncomms10918.

12.

APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis.

Liu Y, Yu JT, Wang HF, Han PR, Tan CC, Wang C, Meng XF, Risacher SL, Saykin AJ, Tan L.

J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):127-34. doi: 10.1136/jnnp-2014-307719. Epub 2014 May 16. Review.

13.

Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment.

Nosheny RL, Insel PS, Truran D, Schuff N, Jack CR Jr, Aisen PS, Shaw LM, Trojanowski JQ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative..

Neurobiol Aging. 2015 Jan;36(1):273-82. doi: 10.1016/j.neurobiolaging.2014.07.036. Epub 2014 Aug 1.

PMID:
25175807
14.

Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.

Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS; Alzheimer's Disease Cooperative Study..

Alzheimers Dement. 2010 Sep;6(5):412-9. doi: 10.1016/j.jalz.2009.12.003.

15.

APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.

Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Rembach A, Martins RN, Rowe CC, Masters CL, Maruff P.

Mol Psychiatry. 2015 Nov;20(11):1322-8. doi: 10.1038/mp.2014.123. Epub 2014 Oct 7.

16.

Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression.

Huijbers W, Mormino EC, Schultz AP, Wigman S, Ward AM, Larvie M, Amariglio RE, Marshall GA, Rentz DM, Johnson KA, Sperling RA.

Brain. 2015 Apr;138(Pt 4):1023-35. doi: 10.1093/brain/awv007. Epub 2015 Feb 11.

17.

β-Amyloid is associated with aberrant metabolic connectivity in subjects with mild cognitive impairment.

Carbonell F, Charil A, Zijdenbos AP, Evans AC, Bedell BJ.

J Cereb Blood Flow Metab. 2014 Jul;34(7):1169-79. doi: 10.1038/jcbfm.2014.66. Epub 2014 Apr 16.

18.

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.

Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM.

Acta Neuropathol. 2014 May;127(5):633-43. doi: 10.1007/s00401-014-1266-2. Epub 2014 Mar 15.

PMID:
24633805
19.

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.

JAMA Neurol. 2014 Oct;71(10):1282-9. doi: 10.1001/jamaneurol.2014.1358.

PMID:
25155658
20.

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative..

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277. Epub 2010 Oct 8.

Supplemental Content

Support Center